在KRAS野生型胰腺管道腺癌中的分子特性和治疗机会
Aakash Desai1, Alexander H Xiao2, Daheui Choi3
1Department of Oncology, Mayo Clinic, Rochester, MN 55902, USA.
Cancers
|May 25, 2024
概括
KRAS野生型胰腺癌是截然不同的,具有可操作的突变. 一名MET转位患者对向治疗反应良好,在这个群体中显示出精准医学的前景.
科学领域:
- 在瘤学瘤学.
- 遗传学 遗传学 是一个
- 分子生物学分子生物学
背景情况:
- 胰腺管腺癌 (PDAC) 是一种具有挑战性的疾病,治疗选择有限.
- 在PDAC中,KRAS突变很常见,但有一部分患者患有野生型KRAS (KRASWT).
- 了解KRASWT PDAC的分子格局对于开发向疗法至关重要.
研究的目的:
- 描述KRASWT PDAC的分子特征.
- 在这个患者子组中探索精准医学方法的潜力.
- 在KRASWT PDAC.中识别可操作的基因变异.
主要方法:
- 对27名KRASWT PDAC患者的分析.
- 瘤样本的整体外体序列和RNA序列.
- 开发一种患者衍生有机体 (PDO) 模型.
- 在PDO的ex vivo药物敏感性测试.
主要成果:
- 转录组分析显示了基于KRAS信号级联基因表达的分层.
- 一名KRASWT PDAC患者的TFG-MET融合基因在体外显示出对crizotinib的敏感性.
- 该患者在2期临床试验中获得了对c-MET抑制剂vebrelitinib的部分和持久反应.
结论:
- 克拉斯沃特PDAC在分子上是截然不同的,并且存在潜在的可操作突变.
- 克拉斯信号级联可能是克拉斯沃特PDAC的关键驱动器.
- 针对性疗法,如c-MET抑制剂,对具有特定遗传变异的KRASWT PDAC患者显示有前途.
更多相关视频
07:08Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
Published on: February 2, 2024
784
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
17.9K
相关概念视频
02:07Tumor Progression
6.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K
02:38The Ras Gene
6.2K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
Ras is a...
6.2K
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
03:03mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K